What Happened?
Cambridge, MA-based Foghorn-Therapeutics Appointed Adrian Gottschalk as Chief Executive Officer
Date of management change: August 13, 2019
Cambridge, MA-based Foghorn-Therapeutics Appointed Adrian Gottschalk as Chief Executive Officer
More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes? Foghorn® Therapeutics ($FHTX) is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control™ platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease. With Gene Traffic Control™ Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.
Adrian Gottschalk is Chief Executive Officer at Foghorn Therapeutics. Previously, Adrian held various senior HR leadership roles in the industry.
News
Other IT executives who recently changed jobs as well: Crowe Vincent, Tate Terry, Kim Albert, Travis Terri, Banzhaf Lori, Franco Julian, Ganzlin Karen, Kaskie Mike, Echevarria Jesus, Parham Dan, Diels Steve
You can find the full directory of IT executives here.
How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.